drugset / Trial / NCT03455764
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation. The interventions involved in this study are: * MCS110 * Dabrafenib * Trametinib
Timeline
- Start
- 2018-09-10
- Primary completion
- 2023-09-05
- Completion
- 2023-09-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | 150 mg | Oral |
| Subject | MCS110 | Monoclonal antibody | 1.25 mg/kg | Intravenous |
| Subject | MCS110 | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | MCS110 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | MCS110 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Trametinib | Small molecule | 2 mg | Oral |